MYND Life Sciences (XCNQ:MYND) EPS (Basic) : C$-0.02 (TTM As of Jul. 2024)

View and export this data going back to 2021. Start your Free Trial

What is MYND Life Sciences EPS (Basic)?

MYND Life Sciences's basic earnings per share (Basic EPS) for the three months ended in Jul. 2024 was C$-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jul. 2024 was C$-0.02.

MYND Life Sciences's EPS (Diluted) for the three months ended in Jul. 2024 was C$-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jul. 2024 was C$-0.02.

MYND Life Sciences's EPS without NRI for the three months ended in Jul. 2024 was C$-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jul. 2024 was -0.04.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

MYND Life Sciences EPS (Basic) Historical Data

The historical data trend for MYND Life Sciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MYND Life Sciences EPS (Basic) Chart

MYND Life Sciences Annual Data

Trend

Oct21

Oct22

Oct23

EPS (Basic)

-0.10

-0.08

-0.03

MYND Life Sciences Quarterly Data
	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
EPS (Basic)	Get a 7-Day Free Trial										-0.01	0.01	-0.01	-0.01	-0.01

MYND Life Sciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

MYND Life Sciences's Basic EPS for the fiscal year that ended in Oct. 2023 is calculated as

Basic EPS (A: Oct. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-1.518	-	0)	/	47.269
	=	-0.03

MYND Life Sciences's Basic EPS for the quarter that ended in Jul. 2024 is calculated as

Basic EPS (Q: Jul. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.379	-	0)	/	46.275
	=	-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.02

MYND Life Sciences (XCNQ:MYND) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

MYND Life Sciences EPS (Basic) Related Terms

Thank you for viewing the detailed overview of MYND Life Sciences's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

MYND Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (XCNQ:MYND) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

MYNDF:USA

Address

105-2248 Elgin Avenue, Port Coquitlam, BC, CAN, V3C 2B2

Website

https://www.myndsciences.com

MYND Life Sciences Inc is a medical biotech drug research and development company. The company is focused on neuro pharmaceutical and novel drug development, diagnostics, and vaccines and is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by different molecular concepts for the applications of psilocybin analogs for overcoming diseases.